Novel application for the JAK inhibitor baricitinib in the treatment of Vogt–Koyanagi–Harada disease: a prospective cohort study
PurposeThe purpose of this study was to prospectively evaluate the clinical efficacy and safety of baricitinib, a selective Janus kinase (JAK)1/JAK2 inhibitor, in the treatment of patients with Vogt–Koyanagi–Harada (VKH) disease.DesignThe study was des…